Shorter Radiotherapy Treatment can Benefit Bowel Cancer Patients During COVID-19 Pandemic

During the COVID-19 pandemic, bowel cancer patients will benefit from the use of effective, shorter, and safer radiotherapy treatment, reports a new study. The findings of the study are published in the journal Radiotherapy and Oncology.// The short course of treatment involves higher-intensity radiation rather than five weeks of radiotherapy, coupled with chemotherapy. Surgery, which normally happens one to two weeks after radiotherapy, can be safely delayed by up to 12 weeks, says the expert panel.

This approach, based on the latest research evidence, will maintain the best chance of successfully treating the disease while at the same time reducing the side effects of treatment and the risks of COVID-19 infection.

Shorter-course radiotherapy avoids the need for chemotherapy, which further suppresses the immune system. It also means significantly fewer hospital appointments, allowing patients to maintain social distancing rules.

David Sebag-Montefiore, Professor of Clinical Oncology at the University of Leeds and Honorary Clinical Oncologist with the Leeds Teaching Hospitals NHS Trust, who led the expert panel, said: "The COVID-19 pandemic is a global emergency and we needed to work very quickly to identify changes that would benefit patients. Our recommendations were published 20 days after our first meeting.

"This process normally takes many months, if not years."

Writing in the journal, the panel, made up of cancer experts from across Europe, say it is also possible that hospitals may struggle to offer the current treatment approaches as COVID-19 impacts on hospital staffing levels.

The 15- strong panel comprised researchers who led the defining studies. Their research shows that surgery can be safely delayed by 12 weeks. The chances of successful treatment are maintained, and post-operative side effects are reduced. This allows surgery to be scheduled after the peak of the pandemic.

The recommendation to use shorter-course radiotherapy follows a major study, funded by the UK Medical Research Council and led by Professor Sebag-Montefiore, which demonstrated the benefit of the one-week course of radiotherapy.

Professor Sebag-Montefiore added: "Our guidelines will result in a very substantial change in treatment across the globe. During the COVID-19 pandemic, our patients will benefit from the use of an effective, shorter, and safer radiotherapy treatment."

Source-Eurekalert